Loading
Low doses of anti-blood-vessel drugs briefly make tumour vessels work better, which helps immune cells and other drugs get in. Scans can find that window for each patient.
Vascular normalisation after low-dose anti-angiogenic therapy is transient and dose-dependent, and DCE-MRI or perfusion CT can measure it patient by patient. Current anti-angiogenic and checkpoint combinations use fixed high doses and fixed schedules, so many patients are likely dosed outside their own normalisation window. Imaging-guided scheduling is a trial design intervention with existing drugs.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, PET (positron emission tomography), Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, MRI, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares MRI, Bevacizumab, Anti-angiogenic therapy.